Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FONTANA study of torvutatug samrotecan alone or in combination in advanced solid tumors
jRCT2031230175Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Open-label trial of AZD5335 in ovarian cancer, endometrial cancer (EC), Non-small cell lung cancer adenocarcinoma (NSCLC) and 1 more (6 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events or serious adverse events and Number of participants with dose-limiting toxicity. Started Sep 2023; status: recruiting.
02
Drugs
AZD5335
03
Conditions
ovarian cancerendometrial cancer (EC)Non-small cell lung cancer adenocarcinoma (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2031230175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230175.